Auxogyn, Inc. Receives CE Mark for Non-Invasive Early Embryo Viability Assessment (Eeva) Test
MENLO PARK, CA--(Marketwire - July 23, 2012) -
| Highlighted Links |
Auxogyn |
"Auxogyn is committed to improving the IVF process and we are pleased to be able to offer the first technological breakthrough in embryo assessment. Eeva is the first and only non-invasive test that provides clinically validated, consistent, objective and actionable information to identify those embryos which are the most appropriate for transfer," said Lissa Goldenstein, president and chief executive officer of Auxogyn. "We are now able to bring clinically relevant discoveries to the field of assisted reproductive health by offering a tool that provides the objective data needed to improve decision-making and patient outcomes during embryo selection in the IVF process."
"We are prepared to begin our commercialization efforts in the EU immediately to make Eeva available to infertility specialists and their patients," added Ms. Goldenstein. "In addition, we have also recently submitted our 510(k) filing to the FDA in order to provide the benefits of Eeva to those in need in the U.S."
The CE mark approval and FDA submission were based on data from a recently completed prospective, multi-center, 160-patient clinical trial that validated the safety and efficacy of Eeva. Results of the trial were presented earlier this month at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting in Istanbul, Turkey. In the study, Eeva was able to predict blastocyst formation at the cleavage stage with 85 percent specificity, reducing the false positive rate from 43 percent to 15 percent compared with traditional morphology selection. Eeva also demonstrated the ability to track and analyze cell division timings with greater than 90 percent accuracy. Additionally, Eeva was able to increase the consistency of embryo assessment across embryologists.
About IVF
Infertility affects one out of every six couples. The demand for assisted reproduction tools and procedures is growing by approximately 10-15 percent per year worldwide due to higher infertility rates caused by an increasing maternal age as more women are starting families later in life. The demand is growing despite the significant cost per cycle and the low success rate with approximately one-third of cycles resulting in a live birth. This necessitates the transfer of multiple embryos and/or conducting multiple cycles, leading to greater physical, emotional, practical and financial costs, before determining if pregnancy can be achieved.
About the Eeva™ Test
Auxogyn's non-invasive Early Embryo Viability Assessment (Eeva) Test is designed to improve IVF outcomes by providing clinicians and patients with objective information that will enable them to more confidently select embryo(s) for transfer. Eeva's proprietary software automatically analyzes embryo development against scientifically and clinically validated cell-division parameters, not only providing novel quantitative information, but also ensuring consistent measurements to assess embryo development versus the manual methods used today in clinical practice. With Eeva's quantitative data for each embryo's potential development, IVF clinics may be able to optimize the treatment path for their patients undergoing IVF procedures.
Eeva is not yet cleared in the United States and is limited to investigational use only.
About Auxogyn
Auxogyn is revolutionizing the field of reproductive medicine by translating scientific discoveries in early embryo development into clinical tools. The Company's flagship product, the Eeva™ Test, delivers consistent, objective and quantitative information regarding embryo viability that reproductive endocrinologists and infertility patients can use to make important treatment decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For more information regarding Auxogyn, please visit www.auxogyn.com.